Doxycycline calcium clinical pharmacology

Jump to navigation Jump to search
Doxycycline calcium
VIBRAMYCIN HYCLATE® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]

Clinical Pharmacology

Tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. They are concentrated by the liver in the bile, and excreted in the urine and feces at high concentrations and in a biologically active form. Doxycycline is virtually completely absorbed after oral administration.

Following a 200 mg dose, normal adult volunteers averaged peak serum levels of 2.6 mcg/mL of doxycycline at 2 hours, decreasing to 1.45 mcg/mL at 24 hours. Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal function (creatinine clearance about 75 mL/min.). This percentage excretion may fall as low as 1–5%/72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min.). Studies have shown no significant difference in serum half-life of doxycycline (range 18–22 hours) in individuals with normal and severely impaired renal function.

Hemodialysis does not alter serum half-life.

Results of animal studies indicate that tetracyclines cross the placenta and are found in fetal tissues.[1]

References

  1. "VIBRAMYCIN MONOHYDRATE (DOXYCYCLINE) POWDER, FOR SUSPENSION VIBRAMYCIN CALCIUM (DOXYCYCLINE CALCIUM) SYRUP VIBRAMYCIN HYCLATE (DOXYCYCLINE HYCLATE) CAPSULE VIBRA-TABS (DOXYCYCLINE HYCLATE) TABLET, FILM COATED [PFIZER LABORATORIES DIV PFIZER INC]". Text " accessdate" ignored (help)

Adapted from the FDA Package Insert.